Stryker Corp Sponsored Canadian Depository Receipt Hedged Reg S stock analysis
Stryker Corp Sponsored Canadian Depository Receipt Hedged Reg S (SYK) Stock Price & Analysis
SYK Stock Chart & Stats
- Day’s Range
- CAD 20.90 - CAD 21.45
- 52-Week Range
- CAD 18.08 - CAD 24.29
- Previous Close
- CAD 20.91
- Volume
- N/A
- Average Volume (3M)
- 16.27K
- Market Cap
- CAD 172.95B
- Enterprise Value
- CAD 169.97B
- Total Cash (Recent Filing)
- N/A
- Total Debt (Recent Filing)
- N/A
- Price to Earnings (P/E)
- 33.6
- Beta
- 1.60
- Next Earnings
- Feb 02, 2027 (Est.)
- EPS Estimate
- N/A
- Last Dividend Ex-Date
- Oct 01, 2026
- Dividend Yield
- 0.56%
Stryker Corp Sponsored Canadian Depository Receipt Hedged Reg S News
SYK FAQ
What was Stryker Corp Sponsored Canadian Depository Receipt Hedged Reg S’s price range in the past 12 months?
What is Stryker Corp Sponsored Canadian Depository Receipt Hedged Reg S’s market cap?
When is Stryker Corp Sponsored Canadian Depository Receipt Hedged Reg S’s upcoming earnings report date?
How were Stryker Corp Sponsored Canadian Depository Receipt Hedged Reg S’s earnings last quarter?
Is Stryker Corp Sponsored Canadian Depository Receipt Hedged Reg S overvalued?
Does Stryker Corp Sponsored Canadian Depository Receipt Hedged Reg S pay dividends?
What is Stryker Corp Sponsored Canadian Depository Receipt Hedged Reg S’s EPS estimate?
How many shares outstanding does Stryker Corp Sponsored Canadian Depository Receipt Hedged Reg S have?
What happened to Stryker Corp Sponsored Canadian Depository Receipt Hedged Reg S’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Stryker Corp Sponsored Canadian Depository Receipt Hedged Reg S?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Stryker Corp Sponsored Canadian Depository Receipt Hedged Reg S
Stryker Corporation functions as a prominent medical technology enterprise, with its operations structured across two main divisions. The Orthopaedics and Spine segment specializes in providing implants for joint replacement procedures (including hips and knees), as well as solutions for trauma and extremities surgeries. This division also furnishes a comprehensive suite of spinal implant products, such as cervical, thoracolumbar, and interbody systems, utilized in addressing spinal injuries, deformities, and degenerative conditions. The MedSurg and Neurotechnology division offers an extensive array of products, encompassing advanced surgical equipment, surgical navigation systems, endoscopic and communication tools, patient handling devices, emergency medical apparatus, and critical care disposable items. This segment also deals in reprocessed and remanufactured medical devices, catering to various medical specialties. Furthermore, its neurotechnology offerings include devices for minimally invasive endovascular techniques, instruments for brain and open skull-based surgical interventions, and orthobiologic and biosurgery products like synthetic bone grafts and vertebral augmentation solutions. It also provides specialized minimally invasive products for treating acute ischemic and hemorrhagic strokes, alongside craniomaxillofacial implants, which include cranial, maxillofacial, and chest wall devices, in addition to dural substitutes and sealants. Stryker distributes its diverse portfolio to medical professionals, hospitals, and other healthcare institutions in approximately 75 countries, leveraging its network of company-owned subsidiaries, regional branches, and independent dealers and distributors. Established in 1941, Stryker Corporation is headquartered in Kalamazoo, Michigan.
- Sector
- General
- Industry
- Medical - Devices
- CEO
- Kevin A. Lobo
- Employees
- 56,000
- Website
- www.stryker.com
- Address
- 1941 Stryker Way, Portage, MI, 49002, US
Stryker Corp Sponsored Canadian Depository Receipt Hedged Reg S (SYK) Earnings & Revenues
SYK Earnings Call
Earnings Call SentimentNeutral
The call was mixed. Stryker delivered solid 7.7% organic sales growth, 10.3% adjusted EPS growth, margin expansion, strong cash generation, healthy capital demand and meaningful product and M&A activity. However, these positives were offset by a material hip and knee market slowdown, weaker-than-expected commercial execution, Peripheral Vascular supply disruption and a reduction to full-year guidance. Management remained confident in the long-term outlook, but the near-term tone was cautious.
View all TSE:SYK earnings summariesTechnical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 14 | 4 | 2 |
| Technical Analysis | 5 | 4 | 1 |
| Moving Averages | 9 | 0 | 1 |













